YuanDa Pharmaceuticals (00512) partner with the global first-in-class nuclear medicine TLX591-Tx to bring good news again, leading the way in prostate cancer treatment with new hope.

Wisdom Financial APP has learned recently that Yuen Da Pharmaceutical (00512) has received positive news regarding its global layout in the field of radiopharmaceuticals. The company's strategic partner in radioisotope conjugate drugs (RDC), Telix Pharmaceuticals Limited (TLX.US), successfully held a Type B meeting with the US FDA. The FDA has confirmed that the international multi-center Phase III clinical trial (ProstACT Global) of the innovative RDC drug TLX591-Tx can proceed to the second part in the United States based on the safety data from the first part.